Literature DB >> 3534764

[The drug combination amoxicillin-clavulanic acid compared to the triple combination ampicillin-gentamicin-metronidazole in the treatment of severe adnexal infections].

N Ciraru-Vigneron, G Bercau, E Sauvanet, R Nguyen Tan Lung, A Felten, J B Leaute, T Zylbertrest, J Barrier.   

Abstract

Forty-four patients with severe pelvic inflammatory disease were randomly divided into two groups. Single drug therapy with the amoxicillin-clavulanic acid was used in 22 patients (group A). The other 22 patients (group B) were given a combination of ampicillin, gentamicin and metronidazole. Clinical results were comparable in both groups with 91% successes and 9% improvements in group A, against 86% successes, 9% failures, and 5% non-interpretable results in group B. The difference between the two groups was not statistically significant (p = 11.6%). 30% of patients in each group had positive serologic tests for Chlamydiae. This had no influence on therapeutic results but led to secondary prescription of a cycline. Because amoxicillin-clavulanic acid is active against aerobic and anaerobic pathogens, including beta-lactamase-producing microorganisms, it is a satisfactory alternative to the ampicillin-gentamicin-metronidazole combination, especially as it is simpler to use, less toxic and less expensive.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3534764

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  4 in total

Review 1.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2013-12-11

Review 2.  Pelvic inflammatory disease.

Authors:  Jonathan D C Ross
Journal:  BMJ Clin Evid       Date:  2008-03-10

3.  Antibiotic therapy for pelvic inflammatory disease.

Authors:  Ricardo F Savaris; Daniele G Fuhrich; Jackson Maissiat; Rui V Duarte; Jonathan Ross
Journal:  Cochrane Database Syst Rev       Date:  2020-08-20

4.  Antibiotic therapy for pelvic inflammatory disease: an abridged version of a Cochrane systematic review and meta-analysis of randomised controlled trials.

Authors:  Ricardo F Savaris; Daniele G Fuhrich; Rui V Duarte; Sebastian Franik; Jonathan D C Ross
Journal:  Sex Transm Infect       Date:  2018-10-19       Impact factor: 3.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.